FDA Approved: EVRYSDI — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Evrysdi (risdiplam) from Genentech, leading to changes to the product label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• EVRYSDI (risdiplam)

Snippet

SUPPL AP for EVRYSDI (RISDIPLAM)